Home/Filings/4/0001225208-18-000493
4//SEC Filing

Phalen Michael P. 4

Accession 0001225208-18-000493

CIK 0000885725other

Filed

Jan 2, 7:00 PM ET

Accepted

Jan 3, 7:53 PM ET

Size

18.1 KB

Accession

0001225208-18-000493

Insider Transaction Report

Form 4
Period: 2017-12-29
Phalen Michael P.
SVP & President, Endoscopy
Transactions
  • Exercise/Conversion

    Common Stock

    2017-12-29$7.16/sh+15,835$113,379113,745 total
  • Exercise/Conversion

    Common Stock

    2018-01-01+13,341111,251 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2017-12-2915,8350 total
    Exercise: $7.16Exp: 2021-02-28Common Stock (15,835 underlying)
  • Tax Payment

    Common Stock

    2018-01-01$24.79/sh4,578$113,489106,673 total
  • Sale

    Common Stock

    2017-12-29$25.25/sh15,835$399,86597,910 total
  • Exercise/Conversion

    Performance Share Units

    2018-01-0113,3410 total
    From: 2017-12-31Exp: 2017-12-31Common Stock (13,341 underlying)
Footnotes (6)
  • [F1]This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan.
  • [F2]Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available.
  • [F3]Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $25.24 to $25.26, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
  • [F4]On February 23, 2015, the reporting person was awarded a target number of performance share units under the Company's 2015 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2015 adjusted free cash flow measured against its 2015 financial plan over the one-year performance period ending December 31, 2015 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2016, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2017.
  • [F5]Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 28, 2012, the first anniversary of the date of grant.
  • [F6]Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock.

Issuer

BOSTON SCIENTIFIC CORP

CIK 0000885725

Entity typeother

Related Parties

1
  • filerCIK 0001483882

Filing Metadata

Form type
4
Filed
Jan 2, 7:00 PM ET
Accepted
Jan 3, 7:53 PM ET
Size
18.1 KB